Abstract
Concurrent platinum-based chemoradiation therapy (cCRT) with or without durvalumab consolidation for 12 months is the current standard of care for patients with unresectable stage III Non-Small Cell Lung Cancer (NSCLC). This study characterized the real-world treatment utilization patterns and associated outcomes after approval of durvalumab for this indication.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
